The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer

ErbB2 overexpression identifies a subclass of breast cancer as ErbB2-positive that is frequently associated with poor prognosis. Current ErbB2-targeted therapies have profoundly improved patient outcomes, but mutations occurring in ErbB2 have been shown to confer drug resistance. Induction of ErbB2...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jinrui, Liu, Shuyan, Li, Qiong, Shi, Yulin, Wu, Yueguang, Liu, Fang, Wang, Shanshan, Zaky, Mohamed Y., Yousuf, Waleed, Sun, Qianhui, Guo, Dong, Wang, Taishu, Zhang, Yingqiu, Wang, Yang, Li, Man, Liu, Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429833/
https://www.ncbi.nlm.nih.gov/pubmed/32327714
http://dx.doi.org/10.1038/s41418-020-0538-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429833/
https://www.ncbi.nlm.nih.gov/pubmed/32327714
http://dx.doi.org/10.1038/s41418-020-0538-8

Ejemplares similares